Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q1 FY2018 Earnings Presentation

52 slides from Daiichi Sankyo's earnings presentation, Jul 31, 2018

  1. Slide 1: Top Management Presentation: Financial Results of FY2018 Q1

    Top Management Presentation Financial Results of FY2018 Q1 (April 1 – June 30, 2018) DAIICHI SANKYO CO., LTD Toshiaki Sai Executive Vice President and CFO July 31, 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa

  3. Slide 3: Agenda

    Agenda  FY2018 Q1 Financial Results  Business Update  R&D Update  Appendix 3

  4. Slide 4: FY2018 Q1 Financial Results

    FY2018 Q1 Financial Results 4

  5. Slide 5: Overview of FY2018 Q1 Results

    Overview of FY2018 Q1 Results (Bn JPY) FY2017 Q1 FY2018 Q1 YoY Results Results -5.6% Revenue 239.1 225.7 -13.4 Cost of Sales 80.1 84.7 +4.7 SG&A Expenses 70.8 65.6 -5.2 R&D Expenses 48.0 45.5 -2.5 -25.7% Operating Profit 40.3 29.9 -10.4 Profit before Tax 42.2 29.6 -12.6 -17.8% Profit attributable to

  6. Slide 6: Revenue

    Revenue Decreased by 13.4 Bn JPY (Decreased by 14.2 Bn JPY excl. forex impact) (Bn JPY) Positive Factors Negative Factors FY2017 Results Japan 239.1 Lixiana +5.4 Olmetec -12.6 Pralia +1.1 Nexium -2.8 Japan -1.6 (incl. vaccines, OTC) 4.8 Loxonin *Incl. impact of price revision in Japan Daiichi Sankyo

  7. Slide 7: Operating Profit

    Operating Profit Decreased by 10.4 Bn JPY (Decreased by 11.5 Bn JPY excl. forex impact) FY2017 Results 40.3 増益 減益 (Bn JPY) Revenue -13.4 Revenue 13.4 incl. forex impact of +0.8 Cost of Sales 5.2 Cost of Sales +5.2 (Cost increased) Product mix due to impact of olmesartan LOE SG&A Expenses 5.5 SG&A Ex

  8. Slide 8: Profit Attributable to Owners of the Company

    Profit Attributable to Owners of the Company Decreased by 5.2 Bn JPY FY2017 Results 29.2 (Bn JPY) Financial Income/ 2.3 (Cost increased) Operating Profit 10.4 Expenses etc. Deterioration of forex gains/ losses Financial Income/ Expenses etc. 2.3 Income Taxes etc. -7.8 (Cost decreased) Impact of the

  9. Slide 9: Revenue: Major Business Units (incl. Forex Impact)

    Revenue: Major Business Units (incl. Forex Impact) (Bn JPY) FY2017 Q1 FY2018 Q1 vs. Forecast YoY Results Results (%) Japan 130.0 123.9 -6.1 24.9% Daiichi Sankyo Healthcare 16.8 18.4 +1.5 24.8% Daiichi Sankyo Inc. 25.0 11.0 -14.0 24.9% Olmesartan 6.8 3.2 -3.6 45.0% Welchol 10.1 4.9 -5.3 19.4% Effient

  10. Slide 10: Revenue: Major Products in Japan

    Revenue: Major Products in Japan (Bn JPY) FY2017 Q1 FY2018 Q1 vs. Forecast YoY (%) Results Results Nexium ulcer treatment 22.6 19.8 -2.8 26.0% Lixiana anticoagulant 9.4 14.7 +5.4 27.3% Alzheimer’s disease Memary treatment 12.5 12.9 +0.4 25.3% Loxonin anti-inflammatory analgesic 9.6 7.9 -1.6 25.5% tr

  11. Slide 11: Business Update

    Dalichi-Sankyo Business Update 11

  12. Slide 12: Lixiana: Growth in Japan

    Lixiana: Growth in Japan Sales  As of FY2018 Q1, Lixiana reached No.2 sales share (%) 50 40 29.0% 30 20 Lixiana Product A 10 Product B Product C 0 Copyright © 2018 IQVIA. Calculated based on JPM FY2014 Q1 - FY2018 Q1 Reprinted with permission 12

  13. Slide 13: Japan: Efforts for Cancer Pain

    Japan: Efforts for Cancer Pain Opioid Switching* *Switching to another opioids is a global standard way for use of opioids recommended by Morphine WHO guidelines etc.  MORPHINE HYDROCHLORIDE HYDRATE POWDER “DAIICHI SANKYO”  MORPHINE HYDROCHLORIDE INJECTION “DAIICHI SANKYO” Fentanyl Oxycodone  FEN

  14. Slide 14: Transfer of Long-listed Products

    Transfer of Long-listed Products  Decided to transfer partial long-listed products in order to invest management resource preferentially to oncology area  Transfer Products: 41 long-listed products manufactured and marketed by Daiichi Sankyo and Daiichi Sankyo ESPHA (ref. Total revenue in FY2017:

  15. Slide 15: LPI: Growth of Iron Franchise

    LPI: Growth of Iron Franchise US IV Iron Market (includes dialysis) $890.2M ($M) $786.6M $900 $690M $800 $700 32.2% $600 25.8% LPI will change its company name to $500 14.1% 32.2% 40.1% “American Regent” in Jan. 2019. 25.8% $400 $300 $200 48.3% 42.5% 36.8% $100 $ 56.6% Sales $ 48.2% Sales $ 42.5% Sa

  16. Slide 16: R&D Update

    R&D Update 16

  17. Slide 17: Major Clinical Pipeline (Oncology)

    CE Major Clinical Pipeline Franchise Project Code Potential Indications Preclinical Phase 1 Pivotal Designation Breast, Gastric, Breakthrough Therapy DS-8201 (HER2) CRC, NSCLC SAKIGAKE ADC U3-1402 (HER3) Breast, NSCLC DS-1062 (TROP2) NSCLC AML 1st/ Quizartinib (FLT3) Relapsed/Refractory Fast Track A

  18. Slide 18: Terminology of HER2

    ADC Terminology of HER2  Organized terminology related to HER2 Commonly Used HER2 Status DS terminology for Future Use HER2 positive IHC 3+ HER2 positive or (HER2 overexpressing*) HER2 overexpressing IHC 2+/ISH + IHC 2+/ISH - HER2 low HER2 negative IHC 1+/ISH - IHC 0 HER2 negative * “Overexpressing

  19. Slide 19: DS-8201: Clinical Program

    ADC DS-8201: Clinical Program As of July 2018 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 Multiple Tumors P1 HER2 positive mBreast Post T-DM1 Pivotal P2 Breakthrough Therapy Designation HER2 positive mBreast Post T-DM1 vs Phys Choice P3 Breast Global HER2 positive mBreast vs T-DM1 P3 HER2 low mBreast

  20. Slide 20: DS-8201: P1 Study Design

    DS-8201: P1 Study Design ASCO 2018 ADC Presentation Dose escalation (Part 1) Dose expansion (Part 2) HNSTD Part 2-a HER2-positive T-DM1 pretreated BC Breast cancer or gastric/GEJ adenocarcinoma* 8.0 mg/kg Administered IV Q3W 3 pts Part 2-b RD 6.4 mg/kg HER2-positive Trastuzumab pretreated GC 6 pts R

  21. Slide 21: DS-8201: P1 Study Demographic

    ADC DS-8201:P1 Study Demographic (5.4, 6.4mg/kg) ASCO 2018 Presentation HER2-Expressing HER2-Positive BC HER2-Low BC HER2-Positive GC Other Cancers N = 111a N = 34b N = 44c N = 51d Age, median (range), years 55.0 (33–77) 54.5 (33–75) 68.0 (38–79) 59 (35–76) ECOG performance status, N (%) 0 71 (64.0)

  22. Slide 22: DS-8201: P1 Study Efficacy

    DS-8201: P1 Study Efficacy ASCO 2018 ADC Presentation Tumor Shrinkage by Tumor Types: (5.4 or 6.4 mg/kg) 80 HER2-Positive Breast Cancer 80 HER2-Low Breast Cancer 60 C h a n g e fro m b a s e lin e (% ) 60 C h a n g e fro m b a s e lin e (% ) 40 N = 104 40 N = 33 20 20 0 0 -2 0 -2 0 -4 0 -4 0 -6 0 -6

  23. Slide 23: DS-8201: P1 Study Efficacy

    DS-8201: P1 Study Efficacy ASCO 2018 ADC Presentation Efficacy Outcomes by Tumor Type (5.4 or 6.4 mg/kg) HER2-Expressing HER2-Positive BC HER2-Low BC HER2-Positive GC Other Cancers N = 111 N = 34 N = 44 N = 51 Confirmed ORR* % (n/N) 54.5% (54/99) 50.0% (17/34) 43.2% (19/44) 38.7% (12/31) DCR % (n/N)

  24. Slide 24: DS-8201: P1 Study Safety

    DS-8201: P1 Study Safety ASCO 2018 ADC Presentation Most Frequent TEAEs (≥10%, 5.4 or 6.4 mg/kg, N = 241) Adverse Events All grades (%) Grade ≥3 (%) Nausea 166 (68.9) 6 (2.5) Gastrointestinal Vomiting 84 (34.9) 4 (1.7) Diarrhea 64 (26.6) 2 (0.8) Constipation 51 (21.2) 0 (0.0) Stomatitis 43 (17.8) 0

  25. Slide 25: DS-8201: P1 Study Safety

    DS-8201: P1 Study Safety ASCO 2018 ADC Presentation Adverse Events of Special Interest (5.4 or 6.4 mg/kg, N = 241) AEs All grades (%) Grade ≥3 (%) AST increased 47 (19.5) 2 (0.8) ALT increased 38 (15.8) 2 (0.8) Blood bilirubin increased 6 (2.5) 1 (0.4) Ejection fraction decreased 2 (0.8) 0 (0.0) Ele

  26. Slide 26: DS-8201: HER2-Low Breast Cancer

    DS-8201: HER2-Low Breast Cancer ASCO 2018 ADC Presentation Tumor Shrinkage Over Time by Tumor Type: (5.4 or 6.4 mg/kg) 100 1 year 80 C h a n g e fro m b a s e lin e (% ) 60 40 20 0 -2 0 -4 0 -6 0 -8 0 -1 0 0 0 10 20 30 40 50 60 70 80 90 100 W eeks Includes subjects who had ≥1 postbaseline scan. Dott

  27. Slide 27: Redefined HER2 Subtype

    ADC Redefined HER2 Subtype Classification by Commonly Used Classification by DS terminology Terminology for Future Use Approx. All Patients of metastatic BC 20% All Patients of metastatic BC n=288,550 n=288,550 HR-/ HR-/HER2 HR+/HER2 positive HR+/HER2 positive HER2 positive positive 6.8% 13.5% 6.8%

  28. Slide 28: DS-8201: Target of HER2-Low P3 Study

    ADC DS-8201: Target of HER2-Low P3 Study All Patients of metastatic BC Target of HER2- n=288,550 positive P2 pivotal and P3 studies HR-/HER2 positive HR+/HER2 positive 6.8% 13.5% N=19,730 N=38,835 HR-/ HR+/HER2 low HER2 low 37.0% 6.9% N=106,623 N=19,869 Focus of HER2 Low Phase 3 Program  Target pop

  29. Slide 29: U3-1402: BC P1/2 Study Overview

    U3-1402: BC P1/2 Study Overview ASCO 2018 ADC Presentation Study Design Demographics Phase 1 Phase 2 BC (N=34) Age, median (range), y 55 (37-81) Dose Escalation Finding Expansion ECOG PS, N(%) 0 25 (74) 1 9 (26) No. of Prior Treatment Regimens, N(%) 8.0mg/kg IV q3 wk 0-2 2 (6) 6.4mg/kg IV q3 wk ≧3 3

  30. Slide 30: U3-1402: BC P1/2 Study Efficacy

    U3-1402: BC P1/2 Study Efficacy ASCO 2018 ADC Presentation Best Percentage Change in Sum of Diameters From Baseline in Target Lesions* Percentage Change in Sum of Longest Diameters Change in Target Lesions rom baseline (%) Maximum Change in Tumor Size 40 20 0 -20 (%) -40 -60 -80 ORR**: 15/32 (47%) -

  31. Slide 31: U3-1402: BC P1/2 Study Safety

    U3-1402: BC P1/2 Study Safety ASCO 2018 ADC Presentation Treatment-Emergent Blood and Liver related AE in ≥ 15% Patients, Dose Escalation Phase (Total N = 34)* All All Grade Grade Preferred Term Grades Preferred Term Grades ≥ 3 (%) ≥ 3 (%) (%) (%) Platelet count ALT increased 13 (38) 3 (9) 23 (68) 1

  32. Slide 32: ADC Franchises: Next Data Point

    ADC ADC Franchises: Next Data Point Sep 2018: World Congress of Lung Cancer (WCLC) DS-8201 P1 NSCLC Abstract: early Sep Oct 2018: European Society for Medical Oncology (ESMO) DS-8201 P1 CRC (plan) Poster abstract: Oct 9th, 00:05CEST Oral abstract: Oct 19th, 12:00 CEST Dec 2018: San Antonio Breast Ca

  33. Slide 33: 7th Project in ADC Franchise (with Glycotope)

    ADC 7th Project in ADC Franchise (with Glycotope) ADC Franchise Clinical stage Project Pre- Potential Indication Discovery Phase 1 Pivotal (Target) Clinical DS-8201 Breast, Gastric, 1 (HER2) CRC, NSCLC U3-1402 2 Breast, NSCLC (HER3) DS-1062 3 (TROP2) NSCLC , DS-7300 4 Solid tumor (B7-H3) DS-6157 5 G

  34. Slide 34: Summary of ADC Franchise

    ADC Summary of ADC Franchise  For HER2-positive BC, contemplating BLA in FY2019  Will not be confirmed before 4Q FY2018 DS-8201  Interim result of HER2-low BC was similar to that of HER2-positive BC  ORR: HER2 low 50.0%, HER2 positive 54.5%  Start HER2-low / HR+ BC study soon  First U3-1402 da

  35. Slide 35: Quizartinib: AML Treatment and QuANTUM Studies

    AML Quizartinib: AML Treatment and QuANTUM Studies Appropriate for Intensive chemo Yes(60-65%)* No(25-30%)* Induction Low *Patients who can not treated by intensive/low intensity chemo(5-10%) Intensive intensity chemo chemo Consolidation Hematopoietic Consolidation QuANTUM- Stem Cell chemotherapy Fi

  36. Slide 36: Quizartinib: QuANTUM-R Study Design

    Quizartinib: QuANTUM-R Study Design EHA 2018 AML Presentation Optional treatments Quizartinib (N = 245) Quizartinib HSCT* Long-term follow-up 30 mg × 15 days  60 mg continuation 2:1 Randomization if QTcF ≤ 450 ms on day 16a Salvage chemotherapy (N = 122) LoDAC (N = 29) HSCT* MEC (N = 40) or FLAG-ID

  37. Slide 37: Quizartinib: QuANTUM-R Study Efficacy

    Quizartinib: QuANTUM-R Study Efficacy EHA 2018 AML Presentation 1.0 HR, 0.76 (95% CI, 0.58-0.98) P = 0.0177 (1-sided, stratified log-rank) Proportion of Patients Alive 0.8 Median overall survival: Quizartinib (N = 245): 6.2 months (95% CI, 5.3-7.2 months) Salvage chemotherapy (N = 122): 4.7 months (

  38. Slide 38: Quizartinib: QuANTUM-R Study Efficacy

    Quizartinib: QuANTUM-R Study Efficacy EHA 2018 AML Presentation Percentage (95% CI) Characteristic Quizartinib Salvage Chemotherapy N = 245 N = 122 Best response CRc 48 (42-55) 27 (19-36) CR 4 (2-7) 1 (0-5) CRp 4 (2-7) 0 (0-3) CRi 40 (34-47) 26 (19-35) PR 21 (16-27) 3 (1-8) ORR (CRc + PR) 69 (63-75)

  39. Slide 39: Quizartinib: QuANTUM-R Study QT Prolongation

    AML Quizartinib: QuANTUM-R Study QT Prolongation Presentation EHA 2018 Percentage QTcF Parameter Quizartinib Salvage Chemotherapy (N = 241) (N = 94) Maximum QTcF intervala Grade 1 35 6 (> 450 ms to ≤ 480 ms) Grade 2 12 0 (> 480 ms to ≤ 500 ms) Grade 3 3 0 (> 500 ms) Maximum QTcF changea > 60 ms 12 1

  40. Slide 40: Pexidartinib: TGCT Overview

    Pexidartinib: TGCT Overview ASCO 2018 BTS Presentation  Tenosynovial Giant Cell Tumor (TGCT) is a rare, locally aggressive, inflammatory, nonmalignant neoplasm1,2  Occurs mainly in the synovium of joints, bursae, or tendon sheaths1,2  Clinical features include swelling, pain, limited range of mot

  41. Slide 41: Pexidartinib: ENLIVEN Study Efficacy

    Pexidartinib: ENLIVEN Study Efficacy ASCO 2018 BTS Presentation 25 Pexidartinib (N = 61) 25 Placebo (N = 59) % Change in Tumor Diameter % Change in Tumor Diameter 0 0 -25 -25 -50 -50 -75 -75 -100 -100 Stable Progressive Overall Response Rate [95% CI] Treatment, N (%) Complete Partial Disease Disease

  42. Slide 42: Pexidartinib: Extreme Example of Effective Treatment

    BTS Pexidartinib: Extreme Example of Effective Treatment ASCO 2018 Presentation 56 years old female Diagnosed TGCT in 1988, followed by multiple surgeries Started Pexidartinib in Sep 2016 and still on-going Baseline pain: 5.6, decreased to 0.6 at week 25* Oct 2016 Nov 2016 June 2017 Sep 2017 May

  43. Slide 43: Pexidartinib: ENLIVEN Study Safety

    Pexidartinib: ENLIVEN Study Safety ASCO 2018 BTS Presentation Pexidartinib Placebo Pexidartinib Liver Function, N (%) Part 1 Part 1 Crossover*1 800 mg/d N = 61 N = 59 N = 30 AST or ALT ≥ 3 × ULN 20 (33) 0 4 (13) TBili ≥ 2 × ULN 3 (5) 0 0 TBili ≥ 2 × ULN and AST or ALT ≥ 3 × ULN 3*2 (5) 0 0 *1 Subjec

  44. Slide 44: Summary of Quizartinib and Pexidartinib

    Summary of Quizartinib and Pexidartinib AML BTS Quizartinib monotherapy  Improved overall survival in relapse/refractory AML FLT3-ITD compared to salvage chemotherapy  Commitment to global submission 2H FY2018  First line study is progressing well Pexidartinib  First-in-class for severe TGCT whe

  45. Slide 45: DS R&D Day 2018

    DS R&D Day 2018  Date: December 12, 2018 (wed) 15:00 – 17:00 (plan)  Location: Daiichi Sankyo Headquarters, Tokyo 45

  46. Slide 46: Appendix

    Appendix - R&D Milestone Events - Major R&D Pipeline - Out-licensing Projects - Abbreviations 46

  47. Slide 47: FY2018 R&D Milestone Events

    FY2018 R&D Milestone Events As of Jul 2018 FY2018 FY2019 Project Study / Indication Q1 Q2 Q3 Q4 Q1 Pexidartinib P3: TGCT (US) Submission Quizartinib P3: QuANTUM-R AML Relapsed/Refractory TLR Submission P1: AML with Quizartinib Study initiation DS-3032 P1: AML with Azacitidine Study initiation P3: HE

  48. Slide 48: Major R&D Pipeline (Oncology)

    Major R&D Pipeline (Oncology) As of Jul 2018 Generic Name/Project Code Number Stage Target indication Region (Class) Phase 1 Phase 2 Phase 3 NDA/BLA mBC (HER2 positive post T-DM1) JP/US/EU/Asia mBC (HER2 positive vs. T-DM1) JP/US/EU/Asia DS-8201 (Anti-HER2 ADC) mGC (HER2 positive post trastuzumab) J

  49. Slide 49: Major R&D Pipeline (SM/Vaccine)

    Major R&D Pipeline (SM/Vaccine) As of Jul 2018 Stage Generic Name/Project Code Number (Class) Target Indication Region Phase 1 Phase 2 Phase 3 NDA AF ASCA Edoxaban/DU-176b (Fxa inhibitor) VTE ASCA Very elderly patients AF JP Specialty medicine (SM) Prasugrel/CS-747 (anti-platelet agent) Ischemic str

  50. Slide 50: Out-licensing Projects

    Out-licensing Projects As of Jul 2018 Pre-clinical Phase1 Phase 2  DS-6051 (NTRK/ROS1 inhibitor) Oncology  DS-1515  DS-2969  Laninamivir (Inflammatory disease/PI3Kδ inhibitor) (Clostridium difficile infection / (CS-8958/Anti-influenza/ Out-licensing  DS-1039 GyrB inhibitor) with Vaxart Inc) (Cy

  51. Slide 51: Abbreviations

    Abbreviations Abbreviation BTD Breakthrough therapy designation CR Complete response DCR Disease control rate DLT Dose limiting toxicity DOR Duration of response EGFR Epidermal growth factor receptor MTD Maximum tolerated dose NSCLC Non-small-cell lung cancer ORR Overall response rate Objective resp

  52. Slide 52: Contact address regarding this material

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: DaiichiSankyoIR@daiichisankyo.co.jp

Daiichi Sankyo Company — Q1 FY2018 Earnings Presentation on 6ix